Prolactin and prostate hypertrophy: A pilot observational, prospective, case-control study in men with prolactinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 6, 2004, Pages 2770-2775

  Colao, Annamaria ^a   Vitale, Giovanni ^a   Di Sarno, Antonella ^a   Spiezia, Stefano ^b   Guerra, Ermelinda ^a   Ciccarelli, Antonio ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b S Maria degli Incurabili Hospital of Naples   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; CABERGOLINE; ISOPROTEIN; PROLACTIN; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; TESTOSTERONE;

ADULT; AGE DISTRIBUTION; CASE CONTROL STUDY; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; CONTROLLED STUDY; DENSITY; DOSE RESPONSE; HEALTH STATUS; HUMAN; MALE; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PROLACTINOMA; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; TESTOSTERONE BLOOD LEVEL; TRANSRECTAL ULTRASONOGRAPHY;

ADULT; CASE-CONTROL STUDIES; DIHYDROTESTOSTERONE; DOPAMINE AGONISTS; ERGOLINES; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC HYPERPLASIA; TESTOSTERONE;

EID: 2942694307     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-032055     Document Type: Conference Paper

References (34)

1. Costello LC, Franklin RB 1994 Effects of prolactin on the prostate. Prostate 24:162-166
2. Reiter E, Hennuy B, Bruyninx M, Cornet A, Klug M, McNamara M, Closset J, Hennen G 1999 Effects of pituitary hormones on the prostate. Prostate 38:159-165
3. Price D 1963 Comparative aspects of development and structure in the prostate. Natl Cancer Inst Monogr 12:351-369
4. Tangbanluekal L, Robinette CL 1993 Prolactin mediates estradiol-induced inflammation in the lateral prostate of Wistar rats. Endocrinology 132:2407-2416
5. Nevalainen MT, Valve EM, Mäkelä SI, Bläuer M, Tuohimaa PJ, Härkönen PL 1991 Estrogen and prolactin regulation of rat dorsal and lateral prostate in organ culture. Endocrinology 129:612-622
6. Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM, Härkönen PL 1997 Prolactin and prolactin receptors are expressed and functioning in human prostate. J Clin Invest 99:618-627
7. Ahonen T, Härkönen PL, Laine J, Rui H, Martikainen PM, Nevalainen MT 1999 Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture. Endocrinology 140:5412-5421
8. Wennbo, H, Kindblom J, Isaksson O, Tornell J 1997 Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology 138:4410-4415
9. Janssen T, Darro F, Petein M, Raviv G, Pasteels JL, Kiss R, Schulman CC 1996 In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate. Cancer 77:144-149
10. Ouhtit A, Morel G, Kelly PA 1993 Visualization of gene expression of short and long forms of prolactin receptor in rat reproductive tissues. Biol Reprod 49:528-536
11. Nevalainen MT, Valve EM, Ingleton PM, Härkönen PL 1996 Expression and hormone regulation of prolactin receptors in rat dorsal and lateral prostate. Endocrinology 137:3078-3088
12. Ahonen TJ, Härkönen PL, Rui H, Nevalainen MT 2002 PRL signal transduction in the epithelial compartment of rat prostate maintained as long-term organ cultures in vitro. Endocrinology 143:228-238
13. Perez-Villamil B, Bordiu E, Puente-Cueva M 1992 Involvement of physiological prolactin levels in growth and prolactin receptor content of prostate glands and testes in developing male rats. J Endocrinol 132:449-459
14. Webber MM 1981 Polypeptide hormones and the prostate. In: Murphy GP, Sandberg AA, Karr JP, eds. The prostatic cell: structure and function, part B. New York: Liss; 63-88
15. Matzkin H, Kaver I, Lewyshon O, Ayalon D, Braf Z 1988 The role of increased prolactin levels under GnRH analogue treatment in advanced prostatic carcinoma. Cancer 61:2187-2191
16. Horti J, Figg WD, Weinberger B, Kohler D, Sartor O 1998 A phase II study of bromocriptine in patients with androgen-independent prostate cancer. Oncol Rep 5:893-896
17. Colao A, Di Sarno A, Cappabianca P, Briganti F, Pivonello R, Di Somma C, Faggiano A, Biondi B, Lombardi G 2003 Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148:325-331
18. Colao A, Marzullo P, Spiezia S, Giaccio A, Ferone D, Cerbone G, Di Sarno A, Lombardi G 2000 Effect of two years of growth hormone/insulin-like growth factor-1 suppression on prostate diseases in acromegalic patients. J Clin Endocrinol Metab 85:3754-3761
19. Colao A, Di Somma C, Spiezia S, Filippella M, Pivonello R, Lombardi G 2003 Effect of growth hormone (GH) and/or testosterone replacement on the prostate in GH-deficient adult patients. J Clin Endocrinol Metab 88:88-94
20. Colao A, Lombardi G 1998 GH and PRL excess. Lancet 352:1455-1461
21. Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G 2000 Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85:2247-2252
22. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A 2001 Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86:5256-5261
23. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G 2003 Withdrawal of long-term cabergoline therapy for tumoral and non-tumoral hyperprolactinemia. N Engl J Med 349:2021-2031
24. Cappabianca P, Lodrini S, Felisati G, Peca C, Cozzi R, Di Sarno A, Cavallo LM, Giombini S, Colao A 2001 Cabergoline-induced CSF rhinorrhea in patients with macroprolactinoma. Report of three cases. J Endocrinol Invest 24:183-187
25. Colao A, Marzullo P, Ferone D, Spiezia S, Cerbone G, Marinò V, Di Sarno A, Lombardi G 1998 Prostatic hyperplasia: an unknown feature of acromegaly. J Clin Endocrinol Metab 83:775-779
26. Colao A, Marzullo P, Spiezia S, Ferone D, Giaccio A, Cerbone G, Pivonello R, Di Somma C, Lombardi G 1999 Effect of growth hormone (GH) and insulin-like growth factor-1 on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH-deficiency and healthy subjects. J Clin Endocrinol Metab 84:1986-1991
27. Compton MM, Witorsch RJ 1983 Proteolytic fragmentation of rat prolactin by the rat ventral prostate gland. Prostate 4:231-246
28. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW 1996 Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 17:639-669
29. Horseman ND, Zhao W, Montecino-Rodriguez E, Tanaka M, Nakashima K, Engle SJ, Smith F, Markoff E, Dorshkind K 1997 Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J 16:6926-6935
30. Nevalainen MT, Valve EM, Ahonen T, Yagi A, Paranko J, Härkönen PL 1997 Androgen-dependent expression of prolactin in rat prostate epithelium in vivo and in organ culture. FASEB J 11:1297-1307
31. Kindblom J, Dillner K, Ling C, Tornell J, Wennbo H 2002 Progressive prostate hyperplasia in adult prolactin transgenic mice is not dependent on elevated serum androgen levels. Prostate 53:24-33
32. Kindblom J, Dillner K, Sahlin L, Robertson F, Ormandy C, Törnell J, Wennbo H 2003 Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. Endocrinology 144:2269-2278
33. Eaton CL 2003 Aetiology and pathogenesis of benign prostatic hyperplasia. Curr Opin Urol 1381:7-10
34. Stattin P, Rinaldi S, Stenman UH, Riboli E, Hallmans G, Bergh A, Kaaks R 2001 Plasma prolactin and prostate cancer risk: a prospective study. Int J Cancer 92:463-465